1. Home
  2. SAGE
  3. SAGE News

Latest Sage Therapeutics Inc. (SAGE) News on November 21, 2024

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
SAGE

Benzinga

a day ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

SAGE

MT Newswires

a day ago

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

SAGE

MT Newswires

a day ago

SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

Sage’s string of research failures continues
SAGE

BioPharma Dive

a day ago

Sage’s string of research failures continues

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
SAGE

Business Wire

a day ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
SAGE

TipRanks

21 days ago

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
SAGE

Zacks

22 days ago

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Biogen, Sage admit a defeat in major depression
SAGE

BioPharma Dive

22 days ago

Biogen, Sage admit a defeat in major depression

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
SAGE

GuruFocus.com

22 days ago

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
SAGE

Zacks

23 days ago

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

23 days ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
SAGE

Zacks

a month ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SAGE

Zacks

a month ago

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
SAGE

GuruFocus.com

a month ago

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares

Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE

Zacks

a month ago

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Sage lays off 55% of R&D workforce and refocuses pipeline
SAGE

Pharmaceutical Technology

a month ago

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
SAGE

GuruFocus.com

a month ago

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
SAGE

Benzinga

a month ago

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
SAGE

Barrons.com

a month ago

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.

Sage to cut one-third of workforce, streamline drug pipeline
SAGE

BioPharma Dive

a month ago

Sage to cut one-third of workforce, streamline drug pipeline

SAGE

MT Newswires

a month ago

SAGE Therapeutics to Cut Workforce by 33%, or 165 Workers, in Reorganization

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
SAGE

Business Wire

a month ago

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
SAGE

Business Wire

a month ago

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics price target lowered to $8 from $9 at Wedbush
SAGE

TipRanks

a month ago

Sage Therapeutics price target lowered to $8 from $9 at Wedbush

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
SAGE

Zacks

a month ago

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

a month ago

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
SAGE

Benzinga

a month ago

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study

SAGE

MT Newswires

a month ago

Sector Update: Health Care

Sage continues downslide as Alzheimer’s study fails
SAGE

BioPharma Dive

a month ago

Sage continues downslide as Alzheimer’s study fails

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

a month ago

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment

SAGE

Investing.com

a month ago

Sage Therapeutics stock drops after disappointing Alzheimer's trial results

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
SAGE

Business Wire

a month ago

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
SAGE

Zacks

a month ago

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

SAGE

MT Newswires

2 months ago

Sector Update: Health Care Stocks Steady Late Afternoon

SAGE

MT Newswires

2 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

SAGE

Investing.com

2 months ago

Sage stock slides as RBC cuts rating to Sell on trial results concerns

SAGE

MT Newswires

2 months ago

Sage Therapeutics Faces High-Risk Outlook Amid Concerns Over Success in Phase 2 Huntington's Disease Trial, RBC Says

SAGE

MT Newswires

2 months ago

RBC Downgrades Sage Therapeutics to Sector Perform From Outperform, Adjusts Price Target to $4 From $10

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
SAGE

Insider Monkey

2 months ago

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
SAGE

Zacks

2 months ago

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
SAGE

TipRanks

2 months ago

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
SAGE

Benzinga

2 months ago

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

SAGE

MT Newswires

2 months ago

Sage Therapeutics Says Biogen Discontinues Collaboration on Sage-324 Program

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
SAGE

Business Wire

2 months ago

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
SAGE

Insider Monkey

2 months ago

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers

SAGE

MT Newswires

2 months ago

Sage Therapeutics Files Registration Statement for Planned Mixed-Shelf Offering

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
SAGE

Zacks

3 months ago

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?

SAGE

MT Newswires

3 months ago

Truist Adjusts Price Target on Sage Therapeutics to $13 From $18, Maintains Hold Rating

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report
SAGE

Simply Wall St.

4 months ago

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations
SAGE

Simply Wall St.

4 months ago

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
SAGE

Zacks

4 months ago

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
SAGE

Zacks

4 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
SAGE

Zacks

4 months ago

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

SAGE

MT Newswires

4 months ago

TD Cowen Downgrades Sage Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $16

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
SAGE

Zacks

4 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

SAGE

MT Newswires

4 months ago

Baird Adjusts Price Target on Sage Therapeutics to $13 From $15, Maintains Neutral Rating

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
SAGE

Zacks

4 months ago

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

SAGE

MT Newswires

4 months ago

Morgan Stanley Halves Price Target on Sage Therapeutics to $11 From $22, Keeps Equalweight Rating

SAGE

MT Newswires

4 months ago

JPMorgan Downgrades Sage Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $18

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
SAGE

Clinical Trials Arena

4 months ago

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
SAGE

Investor's Business Daily

4 months ago

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

SAGE

MT Newswires

4 months ago

Sage Therapeutics, Biogen Stop Development of Investigational Drug for Essential Tremor

Sage Therapeutics Stock Slides as Pipeline Thins
SAGE

Barrons.com

4 months ago

Sage Therapeutics Stock Slides as Pipeline Thins

SAGE

MT Newswires

4 months ago

Wedbush Adjusts Sage Therapeutics' PT to $9 From $15, Maintains Neutral Rating

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SAGE

Zacks

4 months ago

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Biogen, Sage tremor drug fails key trial
SAGE

BioPharma Dive

4 months ago

Biogen, Sage tremor drug fails key trial

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
SAGE

Business Wire

4 months ago

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
SAGE

Clinical Trials Arena

4 months ago

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
SAGE

Zacks

4 months ago

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

SAGE

MT Newswires

4 months ago

Mizuho Securities Lowers Adjusts Price Target on Sage Therapeutics to $16 From $18, Maintains Neutral Rating

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
SAGE

Business Wire

4 months ago

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

SAGE

MT Newswires

4 months ago

JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating

SAGE

MT Newswires

4 months ago

RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating

SAGE

MT Newswires

5 months ago

JPMorgan Adjusts Price Target on Sage Therapeutics to $23 From $28, Maintains Overweight Rating

SAGE's Huntington's Disease Study Meets Primary Endpoint
SAGE

Zacks

5 months ago

SAGE's Huntington's Disease Study Meets Primary Endpoint

SAGE

MT Newswires

5 months ago

Sage Therapeutics Says Phase 2 SURVEYOR Trial Met Primary Endpoint

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
SAGE

Business Wire

5 months ago

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
SAGE

GOBankingRates

5 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
SAGE

Business Insider

5 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
SAGE

Insider Monkey

5 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
SAGE

Reuters

5 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

SAGE

Insider Monkey

5 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
SAGE

AFP

5 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
SAGE

Investor's Business Daily

5 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
SAGE

The Wall Street Journal

5 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.
SAGE

ACCESSWIRE

5 months ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Intermediate Capital Group plc: Notification of Transactions of Directors
SAGE

GlobeNewswire

5 months ago

Intermediate Capital Group plc: Notification of Transactions of Directors

Lyft stock earns multiple upgrades after investor day
SAGE

Yahoo Finance Video

5 months ago

Lyft stock earns multiple upgrades after investor day

Finally, I can make my iPhone look like total crap
SAGE

Engadget

5 months ago

Finally, I can make my iPhone look like total crap

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors
SAGE

GlobeNewswire

5 months ago

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

Stock Split Watch: 3 Growth Stocks That Could Be Next
SAGE

Motley Fool

5 months ago

Stock Split Watch: 3 Growth Stocks That Could Be Next

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers
SAGE

PR Newswire

5 months ago

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen
SAGE

Business Wire

5 months ago

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen

Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SAGE

Business Wire

6 months ago

Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

SAGE

Investing.com

6 months ago

Baird predicts steady growth for SAGE Therapeutics at $15 target

American downgraded, United upgraded: Wall Street's top analyst calls
SAGE

The Fly

6 months ago

American downgraded, United upgraded: Wall Street's top analyst calls

SAGE

MT Newswires

6 months ago

Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target

15 Most Depressed States in the US
SAGE

Insider Monkey

6 months ago

15 Most Depressed States in the US

Sage Therapeutics to Participate in Upcoming May Investor Conferences
SAGE

Business Wire

6 months ago

Sage Therapeutics to Participate in Upcoming May Investor Conferences

Share on Social Networks: